Founded in 2010, Tianming Pharmaceutical, as a leading company in the pharmaceutical industry and intermediates production, is committed to promoting the green transformation and sustainable development of pharmaceutical manufacturing through innovative technologies, based on more than 10 years of industry experience and technology accumulation.
In recent years, Tianming Pharmaceutical has made significant breakthroughs in the field of pharmaceutical intermediates.
With the continuous maturation and optimization of the technology, the R&D production capacity has achieved a qualitative leap, which not only greatly improves the product purity and production efficiency, but also successfully reduces the production cost, providing a more solid and efficient material basis for the research and development of new drugs.
The new high-efficiency synthesis technology independently developed by the company has been successfully applied to the production of a number of intermediates, among which the latest R&D product (R)-3-Chloro-1-phenyl-1-propanol has been successfully commercialized and put into production, which has won wide recognition in the market with excellent product quality and competitive price, highlighting the great potentials of Tianming Pharmaceuticals in the API market.
It has successfully achieved commercial production with excellent product quality and competitive price and won wide recognition in the market, demonstrating the great potential of Tianming Pharmaceutical in the API market.
(R)-3-Chlorophenylpropanol, also known as dextro-3-chlorophenylpropanol, with the chemical formula C9H11ClO and CAS No. 100306-33-0, is a key raw material for the synthesis of a wide range of drugs, the most famous of which is Dapoxetine. As an important pharmaceutical intermediate, its market positioning is high-end, innovative and green, with broad market prospects and full of opportunities.
Dapoxetine, a selective 5-hydroxytryptamine reuptake inhibitor, is used in the treatment of depression and related affective disorders/premature ejaculation in men. Dapoxetine, chemically known as N,N-dimethyl-1-phenyl-3-(1-naphthyloxy)-1-propanamine, contains one chiral carbon atom and a pair of corresponding isomers.
According to the literature [1], the pharmacodynamic activity of the S-isomer is 3.5 times higher than that of the R-isomer, and its chiral center is derived from the key intermediate (R)-3-chlorophenylpropanol.
The synthesis of (R)-3-Chlorophenylpropanol involves a variety of chemical reactions and process steps, including chlorination, addition and reduction reactions.
As a manufacturer, Tianming Pharmaceutical has experienced many challenges in achieving the commercialization and production of this product, but through unremitting efforts and innovations, we have finally succeeded in eliminating all difficulties.
From in-depth R&D to process innovation, Tianming Pharmaceutical R&D staff optimized the conditions of chlorination, addition and reduction reactions to improve the purity and yield of the product, not only developed non-aqueous phase catalytic technology, but also set up a strict quality control system to conduct comprehensive quality testing and monitoring of raw materials, intermediates and finished products.
After completing the small-scale trials in the laboratory, we conducted pilot-scale production tests to verify the stability of the production line and the commercialization potential of the product.
Through the analysis and optimization of the pilot-scale data, the production process and parameters were further adjusted to prepare for large-scale production.
In the future, Tianming Pharmaceutical will continue to increase its R&D investment in the field of pharmaceuticals and major healthcare, and utilize the company’s core technologies in synthetic chemistry, biotechnology and green chemistry to promote the development and industrialization of more innovative products, and provide more efficient and environmentally friendly solutions for the global pharmaceutical industry.
Hechi Vice Mayor Chen Zhijie toured Tianming Pharmaceutical’s facilities, praising its R&D strength and the “Jinan R&D + Hechi production” model.
This non-peptide GLP-1 receptor agonist, now in late-stage clinical trials, is redefining possibilities for diabetes and obesity treatment. Let’s unpack what makes it distinctive from both lab bench and manufacturing perspectives.
Comprehensive guide to 2-methylpentanoic acid’s pharmaceutical synthesis roles, industrial applications (lubricants/flavors), production optimization, GMP quality parameters, and global regulatory compliance requirements.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.